MX2009008873A - Composicion util para el tratamiento de diabetes tipo 2. - Google Patents

Composicion util para el tratamiento de diabetes tipo 2.

Info

Publication number
MX2009008873A
MX2009008873A MX2009008873A MX2009008873A MX2009008873A MX 2009008873 A MX2009008873 A MX 2009008873A MX 2009008873 A MX2009008873 A MX 2009008873A MX 2009008873 A MX2009008873 A MX 2009008873A MX 2009008873 A MX2009008873 A MX 2009008873A
Authority
MX
Mexico
Prior art keywords
diabetes
treatment
type
composition useful
camitine
Prior art date
Application number
MX2009008873A
Other languages
English (en)
Inventor
Franco Gaetani
Ashraf Virmani
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of MX2009008873A publication Critical patent/MX2009008873A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

Se describe el uso de L-carnitina y/o una alcanoil L-carnitina, o una sal farmacéuticamente aceptable de la misma, en combinación con una estatina, para la preparación de un medicamento para el tratamiento de diabetes tipo 2.
MX2009008873A 2007-02-27 2007-11-20 Composicion util para el tratamiento de diabetes tipo 2. MX2009008873A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07103137 2007-02-27
PCT/EP2007/062545 WO2008104239A1 (en) 2007-02-27 2007-11-20 Composition useful for the treatment of type 2 diabetes

Publications (1)

Publication Number Publication Date
MX2009008873A true MX2009008873A (es) 2009-08-28

Family

ID=38093451

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008873A MX2009008873A (es) 2007-02-27 2007-11-20 Composicion util para el tratamiento de diabetes tipo 2.

Country Status (17)

Country Link
US (2) US20100029759A1 (es)
EP (1) EP2124925B1 (es)
JP (2) JP5697337B2 (es)
KR (1) KR101699430B1 (es)
CN (1) CN101616665B (es)
AU (1) AU2007348123B2 (es)
BR (1) BRPI0721333A8 (es)
CA (1) CA2678746C (es)
EA (1) EA016855B1 (es)
ES (1) ES2676529T3 (es)
HK (1) HK1135030A1 (es)
IL (1) IL200192A (es)
MX (1) MX2009008873A (es)
PL (1) PL2124925T3 (es)
PT (1) PT2124925T (es)
SG (1) SG177993A1 (es)
WO (1) WO2008104239A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101699430B1 (ko) * 2007-02-27 2017-01-24 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. ２형 당뇨의 치료에 유용한 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
IT1293067B1 (it) * 1997-07-01 1999-02-11 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico
US20020061301A1 (en) * 1998-05-15 2002-05-23 Olga Bandman Human carbohydrate metabolism enzymes
AU782188B2 (en) * 1999-06-08 2005-07-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antilipemic combinations comprising HMG-COA reductase inhibitors and carnitines
US6245800B1 (en) * 1999-06-08 2001-06-12 Sigma-Tau Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine
US20080102138A1 (en) * 2006-06-21 2008-05-01 Bieley Harlan C Replacement of Vitamins, Minerals and Neurotransmitter Losses from Tobacco Smoking
KR101699430B1 (ko) * 2007-02-27 2017-01-24 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. ２형 당뇨의 치료에 유용한 조성물

Also Published As

Publication number Publication date
WO2008104239A1 (en) 2008-09-04
AU2007348123A1 (en) 2008-09-04
EP2124925A1 (en) 2009-12-02
KR20090115939A (ko) 2009-11-10
KR101699430B1 (ko) 2017-01-24
JP2014040442A (ja) 2014-03-06
SG177993A1 (en) 2012-02-28
JP2010519333A (ja) 2010-06-03
US20150045424A1 (en) 2015-02-12
CA2678746A1 (en) 2008-09-04
HK1135030A1 (en) 2010-05-28
EA200970798A1 (ru) 2010-04-30
PL2124925T3 (pl) 2018-09-28
EA016855B1 (ru) 2012-08-30
US20100029759A1 (en) 2010-02-04
ES2676529T3 (es) 2018-07-20
CN101616665B (zh) 2013-03-27
PT2124925T (pt) 2018-07-12
CN101616665A (zh) 2009-12-30
IL200192A (en) 2015-06-30
IL200192A0 (en) 2010-04-15
BRPI0721333A8 (pt) 2017-12-26
AU2007348123B2 (en) 2013-01-17
EP2124925B1 (en) 2018-06-27
CA2678746C (en) 2018-05-01
JP5697337B2 (ja) 2015-04-08
BRPI0721333A2 (pt) 2014-02-25

Similar Documents

Publication Publication Date Title
EP1991218A4 (en) USE OF CYCLOLIGNANS IN THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES
MY148723A (en) Use of pinolenic acid for the treatment of obesity
TW200716628A (en) Novel compounds
TW200718689A (en) 2-Amino-quinazolin-5-ones
ZA200608029B (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
IL228904A0 (en) Use of milankiperan, or a suitable pharmaceutical salt, in the preparation of a drug for the treatment of fibromyalgia
GB2431346B (en) A combination composition comprising paracetamol and ibuprofen
UA97795C2 (uk) Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
NZ577392A (en) Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
MX2009011900A (es) Curacion de herida diabetica.
SI1861080T1 (sl) Idebenon za zdravljenje miĺ iäśnih distrofij, njegovo pripravo in farmacevtska uporaba
PT2054045E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento da artrite e da dor
IL208751A0 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
MY146803A (en) Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors
MY140538A (en) Substituted n-acyl-2-aminothiazoles
MX2009008873A (es) Composicion util para el tratamiento de diabetes tipo 2.
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
EA200970877A1 (ru) Композиция, пригодная для предупреждения диабета 2 типа и его осложнений у пациентов с предиабетом с резистентностью к инсулину
SI1937245T1 (sl) Spojina uporabna za preprečevanje in zdravljenjeleve ventrikularne hipertofije pri dializiranih pacientih
ZA201005396B (en) 17-hydroxy-19-nor-21-carboxylic acid-steroid y-lactone derivative,use thereof,and medicament containing the derivative
IL206381A0 (en) 17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative

Legal Events

Date Code Title Description
FG Grant or registration